Quinton Moss, MD
Psychiatry · Hamilton, OHNPI 1306993985
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $544,601 of the $629,272 with a category attached, or 86.5%. 30 manufacturers reported payments, led by AbbVie at 34.3% of the total. 2025 is the largest year on record at $234,047, 3.2 times the $73,318 reported in 2019. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,256 payments — averaging $501.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$216K
- Teva Pharmaceuticals USA, Inc.$148K
- Vanda Pharmaceuticals Inc.$107K
- Alkermes, Inc.$93K
- Axsome Therapeutics, Inc.$40K
- Indivior Inc.$12K
- plus $14K from 24 others
Across 31 payments — averaging $405.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$13K
What the payments were for
- Consulting fees$15,0612%
- Speaking & faculty fees$544,60187%
- Travel & lodging$42,6427%
- Food & beverage$26,3994%
- Education$5690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 337 | $215,992 |
| Teva Pharmaceuticals USA, Inc. | 152 | $147,924 |
| Vanda Pharmaceuticals Inc. | 157 | $106,594 |
| Alkermes, Inc. | 180 | $93,330 |
| Axsome Therapeutics, Inc. | 47 | $39,506 |
| Indivior Inc. | 58 | $11,552 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $7,494 |
| Neuronetics, Inc. | 15 | $1,440 |
| Sunovion Pharmaceuticals Inc. | 62 | $906 |
| E.r. Squibb & Sons, L.L.C. | 7 | $879 |
| Otsuka America Pharmaceutical, Inc. | 55 | $821 |
| Neurocrine Biosciences, Inc. | 35 | $656 |
| Johnson & Johnson | 22 | $550 |
| Lundbeck LLC | 34 | $518 |
| Braeburn Inc. | 5 | $239 |
| Idorsia Pharmaceuticals US Inc | 5 | $137 |
| Avanir Pharmaceuticals, Inc. | 6 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $89 |
| Almatica Pharma LLC | 3 | $85 |
| Corium, LLC | 5 | $75 |
| Biogen | 2 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $54 |
| Noven Therapeutics, LLC | 4 | $52 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Tempus AI, Inc | 2 | $30 |
| Tris Pharma Inc | 2 | $29 |
| Eisai Inc. | 1 | $22 |
| USWM, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$629,272 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 68 | $462,499 |
| VraylarCariprazine Hcl | 49 | $73,406 |
| Austedo XrDeutetrabenazine | 12 | $55,229 |
| TrintellixVortioxetine Hydrobromide | 63 | $29,515 |
| Lurasidone Hcl | 35 | $27,716 |
| RexultiBrexpiprazole | 17 | $25,397 |
| CaplytaLumateperone Tosylate | 11 | $21,120 |
| Paliperidone ErPaliperidone | 29 | $6,105 |
| Oxcarbazepine | 42 | $3,468 |
| Clomipramine Hcl | 15 | $3,375 |
| Buspirone Hcl | 99 | $2,687 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 47 | $2,414 |
| Aripiprazole | 24 | $2,230 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $2,229 |
| Lisdexamfetamine Dimesylate | 11 | $1,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $147,924 | $517,72980 claims |
| AbbVieVraylar | $215,992 | $73,40649 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $89 | $29,51563 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $821 | $25,39717 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $7,494 | $21,12011 claims |
| Almatica Pharma LLCSertraline Hcl | $85 | $47934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Hamilton
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.